Tag
The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad th
The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therap
This review synthesizes evidence on the prevalence and prognostic value of right ventricular dysfunction in ATTR-CM and the therapeutic impact of vutrisiran on RV function from the HELIOS-B trial, underscoring RV free wall strain as a key b
This article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 tri
Vutrisiran, an RNA interference therapeutic, significantly improves cardiac function, reduces amyloid burden, and attenuates disease progression in transthyretin amyloid cardiomyopathy as revealed by multiparametric cardiovascular MRI and c
The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyo
Vutrisiran improves cardiac structure, function, and biomarkers, reducing mortality and cardiovascular events in transthyretin amyloid cardiomyopathy over 30 months.
